# FBLN2

Source: https://onco.cc/targets/fbln2/  
OnCo record `fbln2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FBLN2 (Fibulin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Bladder & urothelial cancer, Hepatocellular carcinoma and 4 more.

## Summary

Its binding to fibronectin and some other ligands is calcium dependent. May act as an adapter that mediates the interaction between FBN1 and ELN.

IntOGen calls it a driver in 8 cohorts (2 activating, 5 loss-of-function), covering Bladder Urothelial Carcinoma, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Neuroblastoma, Pancreatic Adenocarcinoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: fibulin 2; Fibulin-2
- Tags: cancer-genes-wave
- Symbol: FBLN2
- Class: tumor-suppressor
- Biology: Its binding to fibronectin and some other ligands is calcium dependent. May act as an adapter that mediates the interaction between FBN1 and ELN. Location: Secreted, extracellular space, extracellular matrix (UniProt). Locus 3p25.1 (HGNC).
- Where found: Pancreatic ductal adenocarcinoma: IntOGen driver in 2 cohorts (PAAD); Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA); Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC); Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC); Prostate cancer: IntOGen driver in 1 cohort (PRAD); Biliary tract cancer: IntOGen driver in 1 cohort (CHOL)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3601: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3601
- UniProt P98095: https://www.uniprot.org/uniprotkb/P98095/entry
- NCBI Gene 2199: https://www.ncbi.nlm.nih.gov/gene/2199
- Ensembl ENSG00000163520: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163520

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/fbln2.json